Type: AT1 receptor selective agonist with the potential to treat acute lung damage / abnormal blood clotting associated with COVID-19. TRV027’s mechanism of action is designed to selectively target the reparative pathway that improves lung function and promote anti-inflammatory effects.
Status: Trevena said August 24 that Imperial College London (ICL) has launched a proof-of-concept study for TRV027 in COVID-19 patients. Through an ongoing collaboration with ICL, the company is evaluating the potential of TRV027 to treat acute lung damage / abnormal blood clotting associated with COVID-19. ICL is sponsoring and funding the study, with additional support through the British Heart Foundation Centre for Research Excellence Award.
The randomized, double-blind, placebo-controlled study will enroll approximately 60 hospitalized, non-ventilated patients aged 18 or older with a confirmed COVID-19 infection. The study’s primary objective is to assess whether TRV027 reduces abnormal clotting associated with COVID-19. The study will also evaluate the effect of TRV027 on lung function and other clinical outcomes. The company currently expects to report top-line data in the first quarter of 2021.
In April 2020, Trevena filed a provisional patent application with the U.S. Patent and Trademark Office covering the use of TRV027 to treat ARDS in COVID-19 patients.
COVID-19: 200 Candidates and Counting
To navigate through the >200 potential therapeutic and vaccine options for COVID-19, GEN has grouped the candidates into four broad categories based on their developmental and (where applicable) clinical progress:
● FRONT RUNNER – the most promising therapeutics/vaccines based on clinical progress, favorable data or both.
● DEFINITELY MAYBE – earlier phases with promising partners, or more advanced candidates in development that have generated uneven data
● KEEPING AN EYE ON… – interesting technology, attracting notable partners, or both, but preliminary data.
● TOO SOON TO TELL – longshots pending additional experimental and/or clinical data.
GEN has also tagged the most common treatment types: